Navigation Links
GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update

ATLANTA, Aug. 11 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm (the Company), developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its financial results and provided an operational update for the six months ended June 30, 2008.

Financial Results for the Three Months and Six Months Ended June 30, 2008

The Company recorded a net loss of $1,284,352 for the three months ended June 30, 2008, compared to $1,333,126 for the same period in 2007. For the six months ended June 30, 2008, the Company's net loss was $1,966,862 as compared to $1,920,407 in 2007. Net losses for 2008 were partially offset by grant revenues of $376,078 and $976,069 for the three month and six month periods, respectively, related to the Company's grant from the National Institutes of Health in support of its HIV/AIDS vaccine development activities. As of June 30, 2008, the Company reported cash balances totaling $3,133,839.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

Management Commentary

Robert McNally, GeoVax's President & CEO, commented, "We are pleased with our six month financial results, including our operational expenses and cash position. Our operational expenses are minimal for a company of our size and stage of clinical trial development. We are particularly pleased with the financing strategy provided by the $10 million common stock purchase agreement with Fusion Capital Fund II, LLC. Funding from the Fusion facility will be utilized for the large Phase 2 preventative AIDS vaccine clinical trial planned to begin this fall and initiation of the therapeutic trial in HIV infected and drug-treated humans."

Dr. McNawarded in late 2007.

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Companies Securities and Exchange Commission filings and reports.

ally continued, "We are also progressing past a signed letter of intent and toward completion of a manufacturing license with Vivalis S.A., a French biopharmaceutical company. Vivalis has a manufacturing platform technology for the MVA portion of the GeoVax vaccine that will significantly improve the production capabilities for the vaccine as the company looks toward worldwide use of this important therapeutic product."

Operational Highlights - 2008:

-- In January 2008, GeoVax was recognized by Georgia Bio, the state trade

organization, as a 2007 "Deal of the Year" award winner for receipt of

the $15 million IPCAVD grant from the National Institutes of Health

(NIH). The award was presented at Georgia Bio's annual awards dinner on

January 24, 2008. This grant is believed to be one of the largest

grants of its kind to be awarded in the last fiscal year.

-- In February 2008, GeoVax announced the addition of company co-founder

Dr. Harriet Robinson to its staff as Vice President of Research &

Development. Dr. Robinson is known worldwide for her outstanding work

on retrovirus biology and a pioneer of DNA vaccines with special

emphasis on HIV/AIDS. Dr. Robinson has published extensively on

HIV/AIDS vaccine research, with more than 150 referred scientific

journal publications, 50 monograph reviews and six book chapters

authored. She has consulted for the U.S. National Institutes of Health,

the U.S. Food and Drug Administration, the Bill and Melinda Gates

Foundation and the World Health Organization. She served as Chief of

Microbiology and Immunology at Emory University's Yerkes National

Primate Research Center and was an Asa Griggs Candler Professor of

Microbiology and Immunology at the Emory University School of Medicine.

Dr. Robinson is the inventor of GeoVax's HIV-1 AIDS vaccine technology

and co-founder of GeoVax Labs, Inc.

-- During February 2008, GeoVax announced that its Vaccine was only the

5th AIDS Vaccine moving forward into Phase 2a human trials by the HIV

Vaccine Trials Network (HVTN), a network supported by the National

Institutes of Health (NIH). GeoVax has completed three Phase 1 human

trials evaluating its HIV/AIDS vaccines with excellent results and has

two additional human trials undergoing data analysis. Due to promising

results from these five trials, GeoVax is pushing forward with plans

for the critically important and larger Phase 2 human trial. GeoVax's

Phase 2a human trial is designated as Protocol # HVTN 205.

-- In March 2008, GeoVax named Dr. Robert McNally as its President and

CEO, effective April 1, 2008. Former President/CEO and company

co-founder Don Hildebrand remained as Chairman of the GeoVax Board of

Directors and continues to be heavily involved in company development,

growth and expansion plans in the AIDS vaccine arena. Dr. McNally has

been a member of the GeoVax Board of Directors since 2006 and was

previously a co-founder and CEO of Cell Dynamics LLC and Cell Design

LLC companies specializing in GMP processing of human cells for

pharmaceutical and therapeutic applications. Dr. McNally was also

co-founder and Sr. Vice President of Clinical Research for CryoLife,

Inc., a pioneering company in transplantable human tissues. He has had

previous experience as European Regional Manager for Intermedics

International, Inc., and European Marketing Manager for Pacesetter

Systems-Europe, Ltd., in the U.K. Dr. McNally serves as a member of the

advisory boards of the Petit Institute for Bioengineering and Dupree

College of Management at the Georgia Institute of Technology. He is an

elected fellow of the American Institute for Medical and Biological

Engineering, and is a past Chairman for the Georgia Biomedical

Partnership, a trade association, and is recipient of the 2004

Biomedical Industry Growth Award for the State of Georgia. Dr. McNally

has a Ph.D. and MSE in Bioengineering from University of Pennsylvania

and an electrical engineering degree (B.E.E.) from Villanova


-- During April and May 2008, the Company raised $1,365,000 in capital

through a private placement of its common stock and warrants sold to

individual accredited investors.

-- In May 2008, the Company entered into a $10 million common stock

purchase agreement with Fusion Capital Fund II, LLC, a Chicago based

institutional investor. Under the agreement, the Company may sell from

time to time up to $10 million of its common stock to Fusion Capital

over a 25-month period, following approval of the Company's

registration statement by the Securities and Exchange Commission

(declared effective on July 1, 2008). GeoVax will use the proceeds to

further its developmental HIV/AIDS vaccine, expected to enter Phase 2

human clinical trials later this year and its upcoming planned

therapeutic trials. The Company has the right to sell shares of its

common stock to Fusion Capital from time to time in amounts ranging

from $80,000 to $1 million, depending on certain conditions, up to

$10 million in the aggregate. The purchase price of the shares will be

based on the prevailing market prices of the Company's shares at the

time of sales without any fixed discount, and the Company will control

the timing and amount of any sales of shares to Fusion Capital. There

are no negative covenants, restrictions on future financings, penalties

or liquidated damages in the agreement.

-- In June 2008, following approval by the Company's shareholders, GeoVax

changed its state of incorporation from Illinois to Delaware.

-- In July 2008, the Company provided an operational update on the

Company's progress towards entering Phase 2 preventative human clinical

trial testing and plans to proceed into therapeutic human trials with

its AIDS vaccine. Five successful human trials evaluating GeoVax AIDS

vaccines had previously been reported. Following are highlights of the


- Phase 2 Preventive Trial -- The Company's planned Phase 2 trial,

which will be conducted by the U.S. NIH-supported HIV Vaccine Trials

Network (HVTN), will involve 225 healthy volunteers from the United

States and South America to further evaluate the safety and

immunogenicity of the GeoVax preventative vaccine (vaccine

administered prior to infection with the HIV virus). In Phase 1

trials, both 1/10th dose and full dose administrations of the GeoVax

vaccine elicited anti-HIV T-cells, whereas the full dose was required

to elicit good frequencies of antibody to the HIV Envelope

glycoprotein. The larger Phase 2 human trial will broaden the base of

safety and immunogenicity data for the full dose of the GeoVax AIDS

vaccine with a view to protecting recipients from developing AIDS

should they be exposed to the virus. The planned Phase 2 human

clinical trial is currently scheduled to start early this fall,

subject to FDA approval.

- Planning for Therapeutic Human Trials -- GeoVax reported summary data

from a pilot study on therapeutic vaccination in simian

immunodeficiency virus (SIV) infected non-human primates with the SIV

prototype of GeoVax's AIDS vaccine. In this small pilot study,

conducted by Dr. Rama Amara at Emory University, two non-human

primates were infected with SIV. At 12 weeks post SIV infection,

conventional anti-viral drug therapy was given to the primates to

reduce the viral RNA infection levels to very low levels creating a

non progressor status for the primate. Then the GeoVax vaccine was

administered. Six weeks following the final vaccination, anti-viral

drug treatment was stopped and the animals were monitored to

determine whether the vaccine could control the SIV infection during

the absence of the drugs. Data from the study revealed outstanding

results with the vaccine controlling the infection with 1000 times

reduction in viral levels in one primate and 100 times in another

primate. The excellent control of the virus infection in the absence

of drug treatment was associated with the vaccine raising the types

of CD4 and CD8 T cells that are found in the rare individuals who

spontaneously control their HIV infections. Based on these excellent

results, planning for a therapeutic trial in infected and

drug-treated humans has been initiated. The intent of therapeutic

vaccination will be to "control" HIV virus levels in infected

individuals to very low levels thus blocking the development of AIDS.

Successful therapeutic AIDS vaccination programs with GeoVax vaccines

would lead to reduction in the use of costly anti-HIV medications and

their often harmful side effects. Further, GeoVax is currently

engaged in negotiations with a NIH sponsored trial network to

administer, conduct and co-sponsor GeoVax's therapeutic human trial

program. Management expects to receive approval for undertaking

formal protocol development in the near future and will report more

detailed plans accordingly.

-- In July 2008, GeoVax and Vivalis S.A., a French biopharmaceutical

company that provides innovative cell-based solutions to the

pharmaceutical industry for the manufacture of vaccines and proteins,

jointly announced the signing of a letter of intent (LOI) for joint

collaboration and commercial license on the use of Vivalis' EBx(R)

technology, to manufacture the MVA component of the GeoVax HIV-1

vaccine. This agreement between GeoVax and Vivalis creates a worldwide

strategic partnership between Vivalis and GeoVax, designed to combine

Vivalis' cutting-edge vaccine manufacturing technology with GeoVax's

promising HIV vaccine. The breakthrough manufacturing technology

developed by Vivalis, through further development collaboration with

GeoVax, will create a new standard for manufacture of the MVA component

of GeoVax's HIV/AIDS vaccine, making present manufacturing technologies

which have limited production capabilities, less competitive. Vivalis'

EBx(R) manufacturing platform, with its increased effectiveness,

superior quality and reliability, will speed time to market MVA vaccine

product availability in ample quantities to meet sizeable demand and

expectedly at a lesser cost. Vivalis' vaccine manufacturing technology

is based on a duck embryonic stem cell substrate platform.

Specifically, the EB66(R) cell line provides continuous growth from a

fully characterized frozen cell bank, without necessitating fertilized

embryo extraction and processing, as with present chicken cell based

technologies. Furthermore, the EB66(R) cell line can be grown in

suspension (without the cells attached to the surface of the growth

vessel) and can be scaled up for growth in giant bioreactors (a cutting

edge industrial method) for large scale production of the MVA viral



Condensed Consolidated Statements of Operations Information

(amounts in thousands, except per share data)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007


Grant Revenue $376 $- $976 $-

Operating expenses:

Research and

development 759 701 1,363 913

General and

administrative 918 650 1,623 1,050

1,677 1,351 2,986 1,963

Other income (expense)

Interest income 16 18 43 43

16 18 43 43

Net loss $(1,284) $(1,333) $(1,967) $(1,920)

Income (loss) per

common share $(0.00) $0.00 $(0.00) $(0.00)


Condensed Balance Sheet Information

(amounts in thousands)

June 30, Dec. 31,

2008 2007


Cash and cash equivalents $3,134 $1,990

Other current assets 138 1,041

Total current assets 3,272 3,031

Property, net 128 75

Other assets 612 140

Total assets $4,012 $3,246

Liabilities and stockholders' equity

Current liabilities $352 $598

Stockholders' equity 3,660 2,648

Total liabilities and stockholders' equity $4,012 $3,246

Shares Outstanding 743,415 731,628

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's HIV/AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax HIV/AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax HIV/AIDS vaccines also may be effective as therapeutics (treatment of people already infected with AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage.

GeoVax's core HIV/AIDS vaccine technologies were developed through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and the GeoVax team.

GeoVax HIV/AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health [NIH), is the largest worldwide clinical trials program dedicated to the development and testing of HIV/AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeoVax Further Strengthens Management Team
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
4. Genaera Corporation Announces Second Quarter Financial Results
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
8. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
(Date:10/9/2017)... Charlotte, N.C. (PRWEB) , ... October 09, 2017 , ... ... Purple announced Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and ... Dr. Stubbs was a member of the winning team for the 2015 Breakthrough Prize ...
Breaking Biology Technology:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a ... intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, ... by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early ... "This is an ...
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
Breaking Biology News(10 mins):